Dr. Gregory Robertson’s research is focused on the field of Mycobacterium tuberculosis host-pathogen interactions with emphasis on the development of novel preclinical tools, use of TB mouse models for drug evaluation, and evaluation of drug activity and resistance in vitro and in vivo. He also leads preclinical animal studies as part of the Consortium for Applied Microbial Metrics including other investigators from the University of California San Francisco, Denver VA Medical Center, and CU Anschutz Medical Campus.
We are looking for talented researchers to join our team!
TB Drug Accelerator
Goal: (i) To identify in vivo active compounds, (ii) to enable more effective hit-to-lead and lead optimization cycles, and (iii) to support the selection of pre-clinical candidates as a service for the TB Drug Accelerator researchers.view project
Development of Novel Proteins Synthesis Inhibitors for MDR Tuberculosis
Goal: This proposal seeks to continue the development of the spectinamides as combination agents for MDR-TB, with a focus on their utility to treat chronic infections and as tools to understand the role of native efflux in tuberculosis drug persistence.
IDENTIFYING CELL PENETRATING PEPTIDES TO TARGET TB
Goal: Tuberculosis is difficult to treat because many drugs are hindered in their ability to penetrate tissues that harbor the pathogen. We propose to overcome this problem by developing new technology based on peptides that recognize and home to TB-infected tissue as a means to target drug payloads to where they are needed most.
Lead Optimization of Novel Azetidine Compound Series Demonstrating New Mechanism of Action for the Treatment of Tuberculosis
Goal: Development of novel tryptophan synthesis inhibitors with activity against M. tuberculosis in vivo.
Validation of Mtb ribosomal RNA as a PD marker of treatment response
Goal: The primary output from this investment is the rapid and comprehensive characterization of novel RNA-based PD markers as measures of treatment-shortening potency.
Characterization of spectinamide 1599 efficacy against different mycobacterial phenotypes.
Tuberculosis (Edinb). 2023 Apr 20;140:102342. doi: 10.1016/j.tube.2023.102342. Online ahead of print.PMID: 37120915
Standardized RS Ratio Metrics To Assess Tuberculosis Antimicrobial Efficacy and Potency.
Antimicrob Agents Chemother. 2023 Jan 24;67(1):e0148322. doi: 10.1128/aac.01483-22. Epub 2023 Jan 9. PMID: 36622159
GSK2556286 Is a Novel Antitubercular Drug Candidate Effective In Vivo with the Potential To Shorten Tuberculosis Treatment.
Antimicrob Agents Chemother. 2022 Jun 21;66(6):e0013222. doi: 10.1128/aac.00132-22. Epub 2022 May 24. PMID: 35607978
Combination of Mycobacterium tuberculosis RS Ratio and CFU Improves the Ability of Murine Efficacy Experiments to Distinguish between Drug Treatments.
Antimicrob Agents Chemother. 2022 Apr 19;66(4):e0231021. doi: 10.1128/aac.02310-21. Epub 2022 Mar 21.PMID: 35311519
Spiropyrimidinetriones: a Class of DNA Gyrase Inhibitors with Activity against Mycobacterium tuberculosis and without Cross-Resistance to Fluoroquinolones.
Antimicrob Agents Chemother. 2022 Apr 19;66(4):e0219221. doi: 10.1128/aac.02192-21. Epub 2022 Mar 10.PMID: 35266826
Lab Principal Investigator [PI]
Research Associate IV
Research Associate III
Research Associate II
Research Associate II
Research Associate I
news and updates view all
A collaborative study, including the CSU Mycobacteria Research Laboratories, provides an important new basis for comparing the effectiveness of different tuberculosis treatments and accelerating the development of shorter regimens.
The Consortium for Applied Microbial Metrics led by scientists at the University of Colorado Anschutz Medical Campus, Colorado State University and University of California San Francisco, combines insights from in vitro, animal and human studies to identify better tuberculosis treatments.
Microbiology room B308
Microbiology room B331